Archive
547 articles, sorted by publication time.
A report of rising share prices reflects capital markets’ urgent imagination around AI drug discovery; but between models, experiments, and clinical trials, the evidence that can truly change medicine still needs time to grow.
Phio is set to hold an online investor-focused fireside chat on the potential of siRNA therapy in cancer; the real scientific weight will still depend on whether delivery, efficacy, and clinical evidence can keep pace with the narrative.
On one side is the future-facing narrative of using algorithms to find new drugs; on the other is the vast legal reality left by herbicide litigation. This summer, Bayer is reminding the market that biotech innovation never happens only in the laboratory.
High-risk, treatment-resistant non-muscle-invasive bladder cancer often pushes patients between repeated recurrence and bladder removal. The significance of the new trial by the Swedish biotech company in collaboration with the University of Iowa is not that efficacy has already been proven, but that a candidate therapy still in early validation is being placed in an important U.S. clinical setting for more rigorous scrutiny.
An early result has brought CAR T back to the center of the solid tumor discussion: if immune cells can find an attackable opening in tumors such as small cell lung cancer, the next test will be whether efficacy is durable enough and toxicity can be controlled.
The three municipal projects may appear to belong separately to landscaping, nighttime tourism, and traditional industry, but together they point to a more difficult question: how can a fast-growing city find boundaries among technology governance, public green space, and the relationship between people and animals?
U.S. researchers have brought pigeons into lung imaging recognition research. The real focus is not to have birds diagnose cancer, but to understand how humans and machines fail in front of early lesions.
A one-day stock surge cannot substitute for experimental evidence; Nexentis’s case is a reminder that the real question for AI drug discovery is not whether a model can imagine molecules, but whether candidates can be synthesized, validated, and moved into the clinic.
Insider Monkey screened AI drug discovery concept stocks by hedge fund holdings, showing that capital is still searching for the next story of R&D efficiency; but what such rankings can tell us is more about market direction than drug success or failure.
A collaboration with a potential total value of about $1.9 billion has put South San Francisco startup Antares Therapeutics on the R&D radar of big pharma; the real test will be whether its early-stage platform and drug candidates can pass through the narrow gate of clinical validation.
The collaboration again pushes the promise of biomedical AI to the front line of drug discovery; but before the disease target, data sources, and experimental evidence are disclosed, it is more like a research and development starting point that deserves rigorous testing.
UCI Health’s REGEN4HD clinical trial has completed neural stem cell therapy in its first patient, moving an idea long confined to the laboratory and surgical planning into humans; but this is not a declaration of efficacy. It is the starting point for safety, post-implantation cell fate, and long-term follow-up.